At 6.1% CAGR, North America Transient Protein Expression Market is Projected to be Worth US$ 518.73 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the North America transient protein expression market was valued at US$ 324.14 million in 2023 and is expected to reach US$ 518.73 million by 2031, registering a CAGR of 6.1% from 2023 to 2031. Increasing applications of protein expression systems and surging popularity of precision medicine are among the critical factors attributed to drive the North America transient protein expression market growth.

Growing urbanization with significant investments in infrastructure rebuilding across the world is the Animal and plant cell-based transient protein expression systems have been in use for the last three decades. Significant advancements in proteomics in recent years have resulted in the availability of newer recombinant protein varieties. The practicality and reproducibility of transient protein expression in animal and plant cells encourage research and development activities to extend their applications in human cell lines. Many contract research and development organizations as well as biopharmaceutical companies, among others, have focused their efforts on incorporating transient protein expression into their production processes. This type of expression system allows them to use different genes to create recombinant proteins without relying on the development of stable cell lines.

The temporary protein expression process finds widespread application in the manufacturing of growth factors, cytokines, hormones, blood products, modified human proteins, and monoclonal antibodies. Moreover, the creation and use of effective bioprocessing techniques have become essential for the commercial synthesis of recombinant proteins with significant therapeutic value. Recent developments in the field of bioprocessing are being applied to provide efficient methods for generating recombinant proteins. Modern Quality by Design concepts, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, high-throughput devices for efficient bioprocess optimization, disposable systems, and process analytics technologies for higher yields of high-quality products are among the recent developments.

Transient protein expression platforms are increasingly being used in vaccine development applications since the onset of the COVID-19 pandemic. Various researchers began studying the SARS-CoV-2 and its variants extensively by using transient protein expression systems. For instance, in March–April 2020, Absolute Antibody (UK) scaled up the production of multigram quantities of different anti-SARS-CoV-2 spike proteins to aid in the development of neutralizing antibodies. Similarly, transient protein expression systems were widely used to produce positive control proteins as a part of the in-vitro diagnostics kits development processes. Thus, the increasing applications of protein expression systems fuel the transient protein expression market growth.

On the contrary, high cost of products hampers the growth of North America transient protein expression market.

Based on product type, the North America transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held 35.1% market share in 2023, amassing US$ 113.81 million. It is projected to garner US$ 185.23 million by 2031 to register 6.3% CAGR during 2023–2031.

In terms of application, the North America transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held 31.6% share of North America transient protein expression market in 2023, amassing US$ 102.37 million. It is anticipated to garner US$ 175.42 million by 2031 to expand at 7.0% CAGR during 2023–2031.

Based on end user, the North America transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held 54.2% share of North America transient protein expression market in 2023, amassing US$ 175.57 million. It is anticipated to garner US$ 288.98 million by 2031 to expand at 6.4% CAGR during 2023–2031.

By country, the North America transient protein expression market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.4% share of North America transient protein expression market in 2023. It was assessed at US$ 270.33 million in 2023 and is likely to hit US$ 437.01 million by 2031, registering a CAGR of 6.2% during 2023–2031.

Key players operating in the North America transient protein expression market are Thermo Fisher Scientific Inc, Merck KGaA, QIAGEN NV, GenScript Biotech Corporation, Promega Corp, Takara Bio Inc, New England Biolabs, Agilent Technologies Inc, Mirus Bio LLC, Bio-Rad Laboratories Inc, Lonza Group AG, and MaxCyte Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com